A phase 1 clinical trial of GS 6679
Latest Information Update: 06 Jan 2023
At a glance
- Drugs GS 6679 (Primary)
- Indications Hepatitis
- Focus Adverse reactions
Most Recent Events
- 06 Jan 2023 New trial record
- 04 Jan 2023 According to a Hookipa Pharma media release, company has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences, Inc. HOOKIPA completed and delivered a regulatory support package for this trial.
- 04 Jan 2023 According to a Hookipa Pharma media release, the first participant in the Phase 1 clinical trial is expected to be dosed in 2023.